The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Press release from Business Wire

ARIAD to Present at the Lazard Capital Markets Healthcare Conference

Wednesday, November 09, 2011

ARIAD to Present at the Lazard Capital Markets Healthcare Conference07:35 EST Wednesday, November 09, 2011 CAMBRIDGE, Mass. (Business Wire) -- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will present at the Lazard Capital Markets Healthcare Conference in New York City. Harvey J. Berger, M.D., chairman and chief executive officer, will provide an overview of the Company's oncology pipeline on Tuesday, November 15 at 1:00 p.m. (ET). Dr. Berger also will discuss the early interim safety and efficacy results from the pivotal PACE trial of ponatinib, ARIAD's investigational pan-BCR-ABL inhibitor, that were published earlier this week in an abstract for presentation at the upcoming annual meeting of the American Society of Hematology being held next month. The ARIAD presentation at the Lazard conference will be webcast live and can be accessed by visiting the investor relations section of the Company's website at A replay of the presentation will also be available and archived on the site for three weeks. About ARIAD ARIAD Pharmaceuticals, Inc. is an emerging global oncology company focused on the discovery, development and commercialization of medicines to transform the lives of cancer patients. ARIAD's approach to structure-based drug design has led to three internally discovered, molecularly targeted product candidates for drug-resistant and difficult-to-treat cancers, including certain forms of chronic myeloid leukemia, soft tissue and bone sarcomas and non-small cell lung cancer. For additional information, visit ARIAD Pharmaceuticals, Inc.For InvestorsMaria E. Cantor, 617-621-2208Maria.cantor@ariad.comorFor MediaLiza Heapes,